Non-aggregating immunostimulatory oligonucleotides
AssigneesNational Institutes of Biomedical Innovation, Health and Nutrition, GeneDesign, Inc.
InventorsKen Ishii, Taiki Aoshi, Hideaki Sato
Life of this patent
Estimating the term…
Abstract
Provided are non-aggregating immunostimulatory oligonucleotides. The present invention also provides a delivery agent for an immunostimulatory-oligonucleotide nucleic acid medicine, said delivery agent including a nucleic acid that contains a phosphorothioated nucleotide. According to another aspect, the present invention further provides an oligonucleotide including a bioactive core, and a nucleic acid that contains a phosphorothioated nucleotide. The present invention yet further provides an immunostimulator including the bioactive core of a type A/D, type B/K, or type C immunostimulatory oligonucleotide.
Claims35
An agent for delivery of an immunostimulatory oligonucleotide nucleic acid medicament, wherein the agent comprises the immunostimulatory oligonucleotide nucleic acid medicament, and a nucleic acid comprising a phosphorothioated nucleotide.
A method for immunostimulation comprising the step of administering an agent comprising a core moiety with biological activity of an A/D type immunostimulatory oligonucleotide to a subject in need thereof.
An oligonucleotide comprising a full length or a core moiety with biological activity of an immunostimulatory oligonucleotide and a nucleic acid comprising a phosphorothioated nucleotide.
Dependencies are inferred from the claim text.